排序方式： 共有51条查询结果，搜索用时 670 毫秒
31.
32.
Sfiligoi G Rassnick KM Scarlett JM Northrup NC Gieger TL 《Journal of the American Veterinary Medical Association》2005,226(8):1368-1374
OBJECTIVE: To compare clinical outcome of dogs with cutaneous mast cell tumors (MCTs) in the inguinal or perineal region with outcome for dogs with MCTs in other cutaneous locations. DESIGN: Retrospective study. ANIMALS: 37 dogs with MCTs in the inguinal or perineal region and 87 dogs with MCTs in other cutaneous locations. PROCEDURE: Information obtained from the medical records included sex, breed, age, histologic grade of all tumors, number and location of all tumors, tumor size (ie, diameter of the tumor), completeness of surgical excision, treatments administered in addition to surgery, and outcome. In all dogs, the primary treatment consisted of surgical excision. RESULTS: Disease-free interval and survival time for dogs with MCTs in the inguinal or perineal region were not significantly different from values for dogs with MCTs in other cutaneous locations. Dogs with incompletely excised tumors, dogs with grade III tumors, and dogs that received systemic treatment were 2, 2.5, and 4 times as likely, respectively, to have a relapse. Factors significantly associated with a shorter survival time were age > 8 years, metastatic disease at the time of initial diagnosis, and tumor relapse. CONCLUSIONS AND CLINICAL RELEVANCE: Results of the present study suggest that dogs with MCTs in the inguinal or perineal region do not have a worse prognosis in regard to disease-free interval or survival time than do dogs with MCTs in other cutaneous locations. Treatment recommendations for dogs with cutaneous MCTs should be based on confirmed predictors of biological behavior, such as histologic grade and clinical stage. 相似文献
33.
Gieger T Rassnick K Siegel S Proulx D Bergman P Anderson C LaDue T Smith A Northrup N Roberts R 《Journal of the American Animal Hospital Association》2008,44(3):116-123
Data from 48 dogs with nasal carcinomas treated with palliative radiation therapy (PRT) were retrospectively reviewed. Factors potentially influencing resolution of clinical signs and survival after PRT were evaluated. Clinical signs completely resolved in 66% of dogs for a median of 120 days. The overall median survival time was 146 days. Duration of response to PRT was shorter in dogs that had clinical signs for <90 days before PRT. Survival times were shorter in dogs that had partial or no resolution of clinical signs after PRT than in dogs that had complete resolution of clinical signs. 相似文献
34.
Single fraction stereotactic radiation therapy (stereotactic radiosurgery) is a feasible method for treating intracranial meningiomas in dogs 
下载免费PDF全文
下载免费PDF全文 Krista L. Kelsey Tracy L. Gieger Michael W. Nolan 《Veterinary radiology & ultrasound》2018,59(5):632-638
The aim of this retrospective, pilot study was to evaluate stereotactic radiosurgery as a method for treating intracranial meningiomas in dogs. Included dogs had an imaging diagnosis of presumed intracranial meningioma, were treated using a standardized stereotactic radiosurgery protocol, and had a follow‐up time of >6 months after stereotactic radiosurgery. A single fraction of 16 Gy stereotactic radiosurgery was delivered to the tumor, with an internal simultaneously integrated boost to a total dose of 20–24 Gy to the central portion of the tumor. Thirty‐two dogs were sampled. One dog was euthanized in the periprocedural period, and 10 of the remaining 31 dogs (31%) experienced an acute adverse event (defined as declining neurologic function due to tumor progression or treatment‐associated complication within the first 6 months after stereotactic radiosurgery), three of which were fatal. Too few subjects (n = 6) had cross‐sectional imaging after stereotactic radiosurgery to determine an objective response rate; however, 17/30 (57%) dogs assessed for response had a perceived clinical benefit from treatment. The overall median survival time was 519 days (95% confidence interval: 330–708 days); 64% and 24% of dogs were alive at 1 and 2 years after stereotactic radiosurgery, respectively. Dogs with infratentorial tumor location and high gradient indices had shorter survival. There were no factors identified which were predictive of acute adverse event. Survival times reported herein are similar to what has previously been reported for other stereotactic and traditional fractionated radiotherapy protocols. Findings therefore supported the use of stereotactic radiosurgery as an alternative method for treating dogs with presumed intracranial meningiomas. 相似文献
35.
Ratterree W Gieger T Pariaut R Saelinger C Strickland K 《Journal of the American Animal Hospital Association》2012,48(2):89-96
The dose-limiting toxicity of doxorubicin is cardiotoxicosis. The authors of this report hypothesized that by using their institution's adopted guidelines (that involve prescreening echocardiography and electrocardiography), they would detect pre-existing cardiac abnormalities that preclude doxorubicin administration in <10% of dogs. Of 101 dogs, only 6 were excluded from doxorubicin administration based on electrocardiogram abnormalities, with a majority of those arrhythmias classified as ventricular premature contractions. One patient was excluded based on echocardiogram alone due to hypertrophic cardiomyopathy. The incidence of cardiotoxicity in treated dogs was 8% (8/101). Additional pretreatment and ongoing studies are indicated to identify risk factors for cardiotoxicity. 相似文献
36.
Michelle Turek Tracy LaDue Jayme Looper Koichi Nagata Keijiro Shiomitsu Michele Keyerleber Julia Buchholz Tracy Gieger Scott Hetzel 《Veterinary radiology & ultrasound》2020,61(4):471-480
Canine oral melanoma (OM) is an aggressive cancer with a high rate of metastasis. Surgery and/or radiotherapy (RT) are effective local treatments, yet many dogs succumb to distant metastasis. Immunotherapy represents an attractive strategy for this potentially immunogenic tumor. The objective of this multi‐institutional retrospective study was to examine the clinical outcome of dogs with OM treated with ONCEPT melanoma vaccine. Most dogs also underwent surgery and/or RT (8 Gy × four weekly fractions). Dogs with distant metastasis at diagnosis and those receiving concurrent chemotherapy were excluded. One hundred thirty‐one dogs treated with ONCEPT were included: 62 had adequate local tumor control defined as complete tumor excision or irradiation of residual microscopic disease; 15 were treated in the microscopic disease setting following an incomplete excision without adjuvant RT; and 54 had gross disease. Median time to progression, median progression‐free survival, and median tumor‐specific overall survival were 304, 260, and 510 days, respectively. In multivariable analysis, presence of gross disease correlated negatively with all measures of clinical outcome. Other negative prognostic indicators were primary tumor ≥2 cm, higher clinical stage (stages 2 and 3), presence of lymph node metastasis at diagnosis, and caudal location in the oral cavity. Radiotherapy had a protective effect against tumor progression. To date, this is the largest reported series of dogs with OM treated with ONCEPT. Several previously reported prognostic indicators were confirmed. 相似文献
37.
38.
39.
AIM: To identify if there was a significant difference in the average daily liveweight gain (ADG) between Thoroughbred foals weaned using two weaning protocols commonly used in New Zealand. METHODS: Sixteen Thoroughbred foals were blocked for sex and age, randomly allocated into progressive (187, SD 33 days; three colts, five fillies) or abrupt (182, SD 28 days; four colts, four fillies) weaning groups, and weighed every second day for 2 weeks either side of weaning, then fortnightly from birth to 480 (SD 31) days old. ADG was calculated to examine the short-term (10 days before weaning, 5 and 10 days post weaning) and long-term (0–6 and 6–16 months of age) effect of the two weaning treatments. RESULTS: ADG was 1.10 (SD 0.091) kg/day before weaning (0–6 months of age) and 0.59 (SD 0.06) kg/day from weaning to 480 (SD 31) days old. At the start of weaning, liveweights of the progressive and abrupt weaning groups were 276.5 (SD 40.3) kg and 257 (SD 15) kg, respectively (p=0.23). For the 5-day period during weaning, irrespective of treatment, there was a significant decrease in ADG of –0.29 (SD 0.49) kg/day and –0.15 (SD 0.30) kg/day for progressive and abrupt weaning, respectively. There was no significant difference in ADG between weaning methods at any measurement period (short or long term) during and after weaning. However, there was large variation between foals in ADG in the 10 days after the weaning process, which may indicate variation in individual foals' responses to being weaned, rather than the weaning treatment. CONCLUSIONS: Weaning, irrespective of method, was associated with a decrease in ADG in the first week after weaning. The method of weaning had no effect on post-weaning ADG either short term, 10 days after weaning, or long term up to 480 days of age. Practically, it may be more important to consider maturity and liveweight as criteria for weaning foals rather than age alone. 相似文献
40.